Dr. Gary Schiller, MD
Claim this profileUCLA Medical Center
Expert in Acute Myeloid Leukemia
Expert in Childhood Cancer
31 reported clinical trials
52 drugs studied
About Gary Schiller, MD
Education:
- Earned an MD (Doctor of Medicine) degree.
Experience:
- Completed a fellowship in hematology and oncology, and a residency in internal medicine.
- Holds board certifications in Internal Medicine and Hematology.
- Serves as a clinical investigator focusing on leukemias, multiple myeloma, and other hematologic malignancies.
- Engages in research on new drugs, therapies, and bone marrow/stem cell transplantation for blood or bone marrow malignancies.
- Recognized as a 2018 Los Angeles Magazine Top Doctor, affiliated with Ronald Reagan UCLA Medical Center and UCLA Santa Monica Medical Center.
Area of expertise
1Acute Myeloid Leukemia
Global LeaderFLT3 positive
CD33 positive
ANC
2Childhood Cancer
Global Leadert(8;21) negative
inv(16) negative
t(16;16) negative
Affiliated Hospitals
Clinical Trials Gary Schiller, MD is currently running
DFP-10917
for Acute Myeloid Leukemia
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), depending on the patient's prior induction treatment.
Recruiting2 awards Phase 34 criteria
SENTI-202
for Blood Cancers
This is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients with CD33 and/or FLT3 expressing blood cancers, including AML and MDS.
Recruiting1 award Phase 14 criteria
More about Gary Schiller, MD
Clinical Trial Related6 years of experience running clinical trials · Led 31 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Gary Schiller, MD has experience with
- Venetoclax
- Azacitidine
- Cytarabine
- Gilteritinib
- Daunorubicin
- SNDX-5613
Breakdown of trials Gary Schiller, MD has run
Acute Myeloid Leukemia
Childhood Cancer
Granulocytic Leukemia
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gary Schiller, MD specialize in?
Gary Schiller, MD focuses on Acute Myeloid Leukemia and Childhood Cancer. In particular, much of their work with Acute Myeloid Leukemia has involved FLT3 positive patients, or patients who are CD33 positive.
Is Gary Schiller, MD currently recruiting for clinical trials?
Yes, Gary Schiller, MD is currently recruiting for 10 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Gary Schiller, MD has studied deeply?
Yes, Gary Schiller, MD has studied treatments such as Venetoclax, Azacitidine, Cytarabine.
What is the best way to schedule an appointment with Gary Schiller, MD?
Apply for one of the trials that Gary Schiller, MD is conducting.
What is the office address of Gary Schiller, MD?
The office of Gary Schiller, MD is located at: UCLA Medical Center, Los Angeles, California 90095 United States. This is the address for their practice at the UCLA Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.